Creek Drive Management Group LLC Makes New $1.04 Million Investment in Capricor Therapeutics, Inc. $CAPR

Creek Drive Management Group LLC purchased a new position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 36,000 shares of the biotechnology company’s stock, valued at approximately $1,039,000.

Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the last quarter. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics in the 4th quarter worth approximately $43,000. GoalVest Advisory LLC acquired a new stake in Capricor Therapeutics in the 4th quarter worth approximately $59,000. Tower Research Capital LLC TRC boosted its position in Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares during the period. Finally, PVG Asset Management Corp bought a new stake in Capricor Therapeutics during the third quarter worth approximately $91,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

NASDAQ CAPR opened at $28.38 on Friday. The stock has a 50-day simple moving average of $30.44 and a 200 day simple moving average of $28.06. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The stock has a market capitalization of $1.64 billion, a PE ratio of -12.23 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities research analysts forecast that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Piper Sandler reaffirmed an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Roth Mkm reiterated a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a research note on Friday, May 15th. Finally, Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $48.36.

Insider Buying and Selling

In other news, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total value of $753,250.00. Following the sale, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 172,529 shares of company stock valued at $5,302,440. Corporate insiders own 9.20% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.